HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Jan 2012 - :1097-0142 [PMID:22252842] [Sharma A] [Koldovsky U] [Xu S] [Mick R] [Roses R] [Fitzpatrick E] [Weinstein S] [Nisenbaum H] [Levine BL] [Fox K] [Zhang P] [Koski G] [Czerniecki BJ]
A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer. Dec 2011 - :1537-4513 [PMID:22130160] [Koski GK] [Koldovsky U] [Xu S] [Mick R] [Sharma A] [Fitzpatrick E] [Weinstein S] [Nisenbaum H] [Levine BL] [Fox K] [Zhang P] [Czerniecki BJ]
Reengineering dendritic cell-based anti-cancer vaccines. Mar 2008 - Immunol. Rev.; 222:1600-065X [PMID:18364007] [Koski GK] [Cohen PA] [Roses RE] [Xu S] [Czerniecki BJ]
Development of vaccines for high-risk ductal carcinoma in situ of the breast. Jul 2007 - Cancer Res.; 67(14):0008-5472 [PMID:17638860] [Czerniecki BJ] [Roses RE] [Koski GK]
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Feb 2007 - Cancer Res.; 67(4):0008-5472 [PMID:17293384] [Czerniecki BJ] [Koski GK] [Koldovsky U] [Xu S] [Cohen PA] [Mick R] [Nisenbaum H] [Pasha T] [Xu M] [Fox KR] [Weinstein S] [Orel SG] [Vonderheide R] [Coukos G] [DeMichele A] [Araujo L] [Spitz FR] [Rosen M] [Levine BL] [June C] [Zhang PJ]
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. Oct 2003 - J. Clin. Oncol.; 21(20):0732-183X [PMID:14551301] [Bedrosian I] [Mick R] [Xu S] [Nisenbaum H] [Faries M] [Zhang P] [Cohen PA] [Koski G] [Czerniecki BJ]
